20205-43-0

Basic information

• Product Name: 6,7-dimethylisatin
• Synonyms: 6,7-dimethylisatin;6,7-dimethyl-1H-indole-2,3-dione(SALTDATA: FREE)
• CAS NO: 20205-43-0
• Molecular Formula: C₁₀H₉NO₂
• Molecular Weight: 175.18396
• Mol File: 20205-43-0.mol
• Article Data: 12

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.25g/cm³
• Refractive Index: 1.586
• CAS DataBase Reference: 6,7-dimethylisatin(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-dimethylisatin(20205-43-0)
• EPA Substance Registry System: 6,7-dimethylisatin(20205-43-0)

Safety Data

• Hazardous Substances Data: 20205-43-0(Hazardous Substances Data)

Usage

General Description

6,7-dimethylisatin is a chemical compound with the molecular formula C10H9NO2. It is a derivative of the naturally occurring compound isatin, and is characterized by the presence of two methyl groups at the 6 and 7 positions of the isatin ring structure. 6,7-dimethylisatin has been found to possess various biological and pharmacological activities, including anti-inflammatory, antioxidant, and antimicrobial properties. It has also been studied for its potential role in the treatment of disorders such as cancer, diabetes, and neurodegenerative diseases. Additionally, 6,7-dimethylisatin has shown promise as a synthetic intermediate in the production of various pharmaceuticals and agrochemicals. Overall, this compound holds potential for further research and development in the fields of medicine and chemical synthesis.

InChI:InChI=1/C10H9NO2/c1-5-3-4-7-8(6(5)2)11-10(13)9(7)12/h3-4H,1-2H3,(H,11,12,13)

Upstream product

• 6579-44-8 2,3-dimethyl-α-isonitrosoacetanilide 
• 79-37-8 oxalyl dichloride 
• 87-59-2 2,3-Dimethylaniline 
• 302-17-0 chloral hydrate 

Downstream Products

• 50419-58-4 2-amino-3,4-dimethylbenzoic acid 
• 76273-37-5 6,7-dimethyl-5H-1,2,4-triazino<5,6-b>indole-3(2H)-thione 
• 76273-36-4 6-(2-amino-3,4-dimethylphenyl)-3-thio-1,2,4-triazine-3,5(2H,4H)dione 
• 924899-55-8 C₁₈H₁₄BrNO₃ 
• 924899-54-7 C₁₈H₁₆N₂O₃ 
• 111395-36-9 2-(β-Anilinovinyl)-3-ethyl-6,7-dimethylindolo<3,2-d>thiazolium iodide 
• 129833-31-4 3,4-dimethyl-2-iodobenzoic acid 
• 117570-53-3 vadimezan 

Relevant articles and documents

Study on synthesis of some substituted N-propargyl isatins by propargylation reaction of corresponding isatins using potassium carbonate as base under ultrasound- and microwave-assisted conditions

Substituted N-propargyl isatins were synthesized by SN2 reaction of corresponding substituted isatins with propargyl bromide in the presence of anhydrous K2CO3 as base. We reported about study on systematically synthesis of these compounds using heating procedures under different reaction conditions, including microwave-assisted heating conditions at power of 100?W (Procedure A), conventional heating conditions in water bath at 50?°C in acetonitrile (Procedure B), and conventional heating conditions in water bath at 50?°C in DMF (procedure C). The best procedure A was deduced based on the investigations on the reaction conditions. Almost all substituted N-propargyl isatins were new, except compounds with R of H, 5-Me, 5-Cl and 5-Br substituents. The structures of the obtained compounds were confirmed by the modern spectroscopic methods.

2-Amino-1,2,3,6-tetrahydro-6-oxocyclopenta[c]fluorene-2-carboxylic acid (FlAib), a completely rigidified, fluoren-9-one-based α-amino acid

The synthesis, optical resolution, determination of absolute configuration and conformational preference, and spectroscopic characteristics of terminally protected (blocked) derivatives and short peptides of 2-amino-1,2,3,6- tetrahydro-6-oxocyclopenta[c]f

CRYSTALLINE FORMS OF DMXAA SODIUM SALT

The present invention relates to pharmaceutically stable crystalline forms of (5, 6-Dimethyl-9- oxo-9H-xanthene-4-yl) acetic acid (DMXAA) sodium salt,- processes for preparing those stable crystalline forms; pharmaceutical compositions comprising at least one of those crystalline forms in solid form or in dissolved form and a pharmaceutically acceptable carrier. Disclosed are methods of using those pharmaceutical compositions to treat tumours, optionally in combination with other active pharmaceutical agents.